MultiCell Technologies, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MCET research report →
About the company
MultiCell Technologies, Inc. (MCET) operates as a biopharmaceutical firm, primarily focused on the creation of innovative therapeutic agents and research tools. Their efforts are directed towards addressing a range of medical challenges, including neurological conditions, liver ailments, various types of cancer, and applications within interventional cardiology and peripheral vascular health.
- CEO
- W. Gerald Newmin
- IPO
- 2000
- Employees
- 2
- HQ
- Woonsocket, RI, US
Price Chart
- Market Cap
- $50.01K
- P/E
- -0.10
- P/S
- 1014.01
- P/B
- -0.31
- EV/EBITDA
- -0.10
- Div Yield
- 0.00%
- Gross Margin
- 100.00%
- Op Margin
- -1465.60%
- Net Margin
- -770.65%
- ROE
- 164.07%
- ROIC
- 81.33%
- Revenue
- $49.318 · 0.00%
- Net Income
- $-380.071 · 69.22%
- EPS
- $-0.00 · 83.33%
- Op Income
- $-722.807
- FCF YoY
- 13.01%
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- -35.68
- Avg Volume
- 342.43K
Get TickerSpark's AI analysis on MCET
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 16, 05 | ALTIG ANTHONY E | other | 10,294 |
| Sep 15, 05 | ALTIG ANTHONY E | other | 50,000 |
| Sep 15, 05 | ALTIG ANTHONY E | other | 0 |
Our MCET coverage
Recent articles, reports, and earnings notes.
No research on MCET yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate MCET report →Similar companies
Peers in the same neighborhood.